After today, andexanet alfa (Andexxa; AstraZeneca) will no longer be made or sold in the United States, according to an alert from the US Food and Drug Administration.

By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Gaxiola López shaped the field of interventional cardiology, with colleagues saying he’ll be remembered as a “visionary.” ...

Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.

Angina patients with no obstructive CAD had no worse outcomes over 15 years, perhaps because they got the care they needed.

Understanding the athlete heart in light of normal aging and CV risk requires a nuanced look at imaging findings, the paper ...

Achieving remission from prediabetes appears to substantially lower the risk of cardiovascular death or hospitalization for heart failure decades later, according to global registry data.

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.

It’s not yet known whether a fibroid diagnosis could enhance risk stratification or how best to prevent ASCVD in these ...

The US Food and Drug Administration has approved the use of lerodalcibep (Lerochol) to reduce LDL cholesterol alongside ...